The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future
暂无分享,去创建一个
[1] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. , 2020, The New England journal of medicine.
[2] Jing Yuan,et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.
[3] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[4] L. Papazian,et al. Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure. , 2020, JAMA.
[5] A. Zangrillo,et al. Respiratory Parameters in Patients With COVID-19 After Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit. , 2020, JAMA.
[6] Emily G McDonald,et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.
[7] Jacques LeLorier,et al. Head to head comparison of the propensity score and the high-dimensional propensity score matching methods , 2016, BMC Medical Research Methodology.
[8] Sinan Aral,et al. The spread of true and false news online , 2018, Science.
[9] H. Larson. Blocking information on COVID-19 can fuel the spread of misinformation , 2020, Nature.
[10] Matthew J. Salganik,et al. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: “STROBE-RDS” statement , 2015, Journal of clinical epidemiology.
[11] K. Schulz,et al. Bias and causal associations in observational research , 2002, The Lancet.
[12] David A Chambers,et al. Big Data and Large Sample Size: A Cautionary Note on the Potential for Bias , 2014, Clinical and Translational Science.
[13] C. Naylor,et al. Counteracting Health Misinformation: A Role for Medical Journals? , 2019, JAMA.
[14] Kwok-Hung Chan,et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.
[15] L. Rodríguez-Mañas,et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study , 2020, The Lancet.
[16] R. Wenzel. Medical Education in the Era of Alternative Facts. , 2017, The New England journal of medicine.
[17] Raina M. Merchant,et al. Protecting the Value of Medical Science in the Age of Social Media and “Fake News” , 2018, JAMA.
[18] A. Fauci,et al. Research in the Context of a Pandemic , 2020, The New England journal of medicine.
[19] Deepak L. Bhatt,et al. Twitter-based learning for continuing medical education? , 2020, European heart journal.
[20] Sanjay Kumar. In India, Hindu pride boosts pseudoscience. , 2019, Science.
[21] Spiros C. Denaxas,et al. Avoidable flaws in observational analyses: an application to statins and cancer , 2019, Nature Medicine.
[22] W. Alhazzani,et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine , 2020, Journal of Clinical Epidemiology.
[23] S. Barton,et al. Which clinical studies provide the best evidence? , 2000, BMJ : British Medical Journal.
[24] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[25] Lee-Jen Wei,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.
[26] M. Dougan,et al. Improving Clinical Trial Enrollment - In the Covid-19 Era and Beyond. , 2020, The New England journal of medicine.
[27] David R. Holtgrave,et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.
[28] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[29] R. Thaler,et al. Nudge: Improving Decisions About Health, Wealth, and Happiness , 2008 .
[30] A. Caplan,et al. Adverse Consequences of Rushing a SARS-CoV-2 Vaccine: Implications for Public Trust. , 2020, JAMA.
[31] A. Hackshaw,et al. Small studies: strengths and limitations , 2008, European Respiratory Journal.
[32] D. Raoult,et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.
[33] Y. Hu,et al. On the use of corticosteroids for 2019-nCoV pneumonia , 2020, The Lancet.
[34] P. Rosenbaum. Discussing hidden bias in observational studies. , 1991, Annals of internal medicine.
[35] M. Pencina,et al. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.
[36] G. Hripcsak,et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.
[37] R. Bruno,et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[38] Minzhang Zheng,et al. The online competition between pro- and anti-vaccination views , 2020, Nature.
[39] C. White,et al. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19 , 2020, Annals of Internal Medicine.
[40] J. Peabody. An organizational analysis of the World Health Organization: narrowing the gap between promise and performance. , 1995, Social science & medicine.
[41] Anthony F. J. van Raan,et al. Citation Analysis May Severely Underestimate the Impact of Clinical Research as Compared to Basic Research , 2012, PloS one.
[42] Thomas Jaki,et al. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report , 2020, The New England journal of medicine.
[43] A. Phelan,et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.
[44] G. Gamble,et al. Media Coverage, Journal Press Releases and Editorials Associated with Randomized and Observational Studies in High-Impact Medical Journals: A Cohort Study , 2015, PloS one.
[45] Wen-Ying Sylvia Chou,et al. Addressing Health-Related Misinformation on Social Media. , 2018, JAMA.
[46] P. Farmer,et al. WHO's Next - The United States and the World Health Organization. , 2020, New England Journal of Medicine.
[47] D. Rubin. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials , 2007, Statistics in medicine.
[48] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[49] David A. Broniatowski,et al. Weaponized Health Communication: Twitter Bots and Russian Trolls Amplify the Vaccine Debate , 2018, American journal of public health.
[50] Amit N. Patel,et al. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.
[51] Christopher J. Rush,et al. Association is not causation: treatment effects cannot be estimated from observational data in heart failure , 2018, European heart journal.
[52] Amit N. Patel,et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.
[53] Y. Hu,et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.
[54] Jeffrey Brainard,et al. Scientists are drowning in COVID-19 papers. Can new tools keep them afloat? , 2020 .
[55] John S. Brownstein,et al. Predicting social response to infectious disease outbreaks from internet-based news streams , 2017, Ann. Oper. Res..
[56] R. Collins,et al. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.
[57] N. Freemantle,et al. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research , 2013, BMJ.
[58] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[59] T. Fojo,et al. Hazard ratios in cancer clinical trials—a primer , 2012, Nature Reviews Clinical Oncology.
[60] T. Lüscher,et al. Twitter promotion predicts citation rates of cardiovascular articles: a preliminary analysis from the ESC Journals Randomized Study. , 2020, European heart journal.
[61] Medical Misinformation: Vet the Message! , 2019, European heart journal.
[62] M. Hernán,et al. Win-win: Reconciling Social Epidemiology and Causal Inference. , 2019, American journal of epidemiology.
[63] C. Torp‐Pedersen,et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. , 2020, JAMA.
[64] G. Koh,et al. Faculty Opinions recommendation of Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. , 2020 .